Skip to main content
https://www.highperformancecpmgate.com/rgeesizw1?key=a9d7b2ab045c91688419e8e18a006621

AstraZeneca says third dose helps against Omicron

AstraZeneca vaccine
A test tube labelled with the Vaccine is seen in front of AstraZeneca logo in this illustration taken, September 9, 2020. REUTERS/Dado Ruvic/Illustration

AstraZeneca said on Thursday that preliminary data from a trial showed that its COVID-19 shot, Vaxzevria, generated an increase in antibodies against the Omicron and other variants when given as a third booster dose.

The increased response, also against the Delta variant, was seen in a blood analysis of people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.

AstraZeneca has developed the vaccine with researchers from the University of Oxford, and lab studies conducted by the university last month already found a three-dose course of Vaxzevria boosted antibody levels in the blood against the rapidly spreading Omicron variant.

The brief statement on Thursday, which did not include specific data, was the first by AstraZeneca on the protective potential of Vaxzevria as a booster shot following a two shot-course of either an mRNA based vaccine or Vaxzevria. Vaccines base on mRNA technology are made by BioNTech-Pfizer and Moderna.

The company said the findings “add to the growing body of evidence supporting Vaxzevria as a third dose booster irrespective of the primary vaccination schedules tested”.

The data on Vaxzevria’s potential as a booster came from a comparative analysis in a trial testing a redesigned vaccine which uses the vector technology behind Vaxzevria but targeting the now-superseded Beta variant. AstraZeneca is trying to show the Beta-specific vaccine has potential also against other variants and more trial data is expected during the first half of the year.

Separately, Oxford University and AstraZeneca last month started work on a vaccine specifically targeting Omicron though Astra – as well as other vaccine makers in similar development projects – have said it was not yet clear whether such an upgrade was needed.

A major British trial in December found that AstraZeneca’s shot increased antibodies when given as a booster after initial vaccination with its own shot or Pfizer’s, but that was before the explosive spread of the Omicron variant.

However, the study at the time concluded that mRNA vaccines made by Pfizer and Moderna gave a biggest boost to antibodies when given as a third dose.

AstraZeneca and its contract manufacturing partners have supplied over 2.5 billion doses globally of its vaccine, even though it is not approved in the United States, while BioNTech-Pfizer have shipped about 2.6 billion doses.

Source: ARY News


Comments

Post a Comment

Popular posts from this blog

Uber co-founder Garrett Camp steps back from board director role

Uber co-founder Garrett Camp is relinquishing his role as a board director and switching to board observer — where he says he’ll focus on product strategy for the ride hailing giant. Camp made the announcement in a short Medium post in which he writes of his decade at Uber: “I’ve learned a lot, and realized that I’m most helpful when focused on product strategy & design, and this is where I’d like to focus going forward.” “I will continue to work with Dara [Khosrowshahi, Uber CEO] and the product and technology leadership teams to brainstorm new ideas, iterate on plans and designs, and continue to innovate at scale,” he adds. “We have a strong and diverse team in place, and I’m confident everyone will navigate well during these turbulent times.” The Canadian billionaire entrepreneur signs off by saying he’s looking forward to helping Uber “brainstorm the next big idea”. Camp hasn’t been short of ideas over his career in tech. He’s the co-founder of the web 2.0 recommendatio...
Post a Comment
Read more

Drone crash near kids leads Swiss Post and Matternet to suspend autonomous deliveries

A serious crash by a delivery drone in Switzerland have grounded the fleet and put a partnership on ice. Within a stone’s throw of a school, the incident raised grim possibilities for the possibilities of catastrophic failure of payload-bearing autonomous aerial vehicles. The drones were operated by Matternet as part of a partnership with the Swiss Post (i.e. the postal service), which was using the craft to dispatch lab samples from one medical center for priority cases. As far as potential applications of drone delivery, it’s a home run — but twice now the craft have crashed, first with a soft landing and the second time a very hard one. The first incident, in January, was the result of a GPS hardware error; the drone entered a planned failback state and deployed its emergency parachute, falling slowly to the ground. Measures were taken to improve the GPS systems. The second failure in May, however, led to the drone attempting to deploy its parachute again, only to sever the line...
Post a Comment
Read more

How the world’s largest cannabis dispensary avoids social media restrictions

Planet 13 is the world’s largest cannabis dispensary. Located in Las Vegas, blocks off the Strip, the facility is the size of a small Walmart. By design, it’s hard to miss. Planet 13 is upending the dispensary model. It’s big, loud and visitors are encouraged to photograph everything. As part of the cannabis industry, Planet 13 is heavily restricted on the type of content it can publish on Instagram, Facebook and other social media platforms. It’s not allowed to post pictures of buds or vapes on some sites. It can’t talk about pricing or product selection on others.   View this post on Instagram   A post shared by Morgan Celeste SF Blogger (@bayareabeautyblogger) on Jan 25, 2020 at 7:54pm PST Instead, Planet 13 encourages its thousands of visitors to take photos and videos. Starting with the entrance, the facility is full of surprises tailored for the ‘gram. As a business, Planet 13’s social media content is heavily restricted a...
3 comments
Read more